Who does what in a clinical trial? A statistician’s map of the study team
One of the fastest ways to become useful in clinical research is to understand who owns which decision. Many analytical mistakes begin as ownership mistakes.
The idea in plain language
Sponsors oversee the study; investigators have medical responsibility at sites; CRAs monitor site conduct; Data Management builds and cleans data; Biostatistics defines methods; programmers produce datasets and outputs; Safety, Regulatory and QA bring different control perspectives.
The statistical or technical layer
Cross-functional interpretation matters because a high deviation rate can reflect protocol complexity, training, staffing, late entry, monitoring delay or true noncompliance. No single function sees the full chain.
For a statistician, the useful habit is to ask what generated the number. A rate can move because the underlying process changed, because the denominator changed, because the data cut moved, or because a configuration/model version changed. A probability can be poorly calibrated. A rank can move even when absolute risk barely changes. That is why clinical analytics needs both mathematics and process context.
Where RBQM enters
CMP brings cross-domain evidence together; SPOT gives site-level context. The platform connects evidence without replacing professional accountability.
Aomics' RBQM architecture deliberately separates detection, precision, prioritization, site context, workflow and governance. The separation matters: it reduces double counting, keeps methods testable and helps the user understand whether a value is a measurement, a statistical signal, a prioritization score or a human decision.
Practical example
A site’s late-entry rate rises. Operations knows the coordinator resigned; the CRA knows a replacement is training; Safety confirms SAE processing is unaffected.
The right next step is usually not “act because the dashboard is red.” First verify the source and data cut. Then inspect the denominator, trend, uncertainty and peer context. Ask whether the pattern persists and whether another independent source supports it. Only then move to an investigation hypothesis or an operational proposal.
What I would check
- Who owns the process?
- Who validates clinical meaning?
- Who can authorize action?
- Who retains the evidence trail?
- Can I reproduce the result from the same data cut and configuration?
- Has the function that owns the underlying process reviewed the evidence?
The mistake I see most often
Reading the team as a hierarchy rather than complementary expertise.
The broader lesson is to match the statistical tool to the decision question. A ranking helps answer “where should we look first?” It does not answer “what caused the problem?” A correlation can suggest a relationship; it does not establish responsibility. A forecast creates time to investigate; it does not make the future certain.
Aomics resources
Clinical data science and biometricsAdaptrials
Adaptive trial design and analyticsRBQM-ai
Clinical quality intelligence and monitoring
Aomics GmbH provides clinical data science, biostatistics, statistical programming and related biometrics services. Adaptrials is relevant to prospective study design and adaptive analytics. RBQM-ai focuses on Quality by Design, centralized monitoring, site oversight, QTL surveillance, predictive risk, signal-to-action and audit-ready evidence.
Frequently asked questions
What is the practical point of clinical trial team roles?
Sponsors oversee the study; investigators have medical responsibility at sites; CRAs monitor site conduct; Data Management builds and cleans data; Biostatistics defines methods; programmers produce datasets and outputs; Safety, Regulatory and QA bring different control perspectives.
Where does this sit in RBQM-ai?
This topic connects mainly to M01, M07, M08. The platform keeps the analytical responsibility separate from human decision authority.
Can the software make the final decision?
No. The system provides evidence and prioritization. Qualified study, medical, operational, safety, quality or regulatory professionals remain responsible for consequential decisions.
Scientific and regulatory references
- ICH E6(R3) Good Clinical Practice
- FDA: A Risk-Based Approach to Monitoring of Clinical Investigations — Q&A
Editorial note: Educational content only. Always check the current study protocol, SAP, monitoring plan, SOPs and applicable official regulator/guideline sources.